Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report

Transplant Proc. 2008 Jan-Feb;40(1):302-4. doi: 10.1016/j.transproceed.2007.11.011.

Abstract

Acute humoral rejection (AHR) is generally less responsive to conventional anti-rejection treatment with consequent allograft losses. Therapeutic options include antilymphocyte antibody (ATG), intravenous immunglobulin (IVIG), plasmapheresis, or immunoadsorption with protein A together with intensification of immunsuppression with a tacrolimus/mycophenolate mofetil combination. This report describes a transplant recipient who responded to rituximab therapy as treatment for steroid-, ATG-, IVIG-, and plasmapheresis-resistant AHR.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Complement C4b / analysis
  • Female
  • Graft Rejection / drug therapy*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation / pathology*
  • Middle Aged
  • Peptide Fragments / analysis
  • Polycystic Ovary Syndrome / complications
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Peptide Fragments
  • Rituximab
  • Complement C4b
  • complement C4d